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model and discounted at an annual rate of 3%. Other model outputs, such as screen-and clinical-detected cancers and cancer deaths, were also reported.
Cost data:
The economic analysis included the costs of mammography, subsequent diagnostic work-up, BC treatment and personal time associated with distinct visits for diagnostic work-up. The resource use data came from the DMIST. Diagnostic and screening costs were derived from Medicare reimbursements. BC treatment costs were obtained from previous publications. Personal costs were valued on the basis of average wages plus non-health benefits for women aged ≥35 years. The long-term costs were discounted at an annual rate of 3%. The price year was 2005 and the costs were in US dollars ($).
Analysis of uncertainty:
The issue of uncertainty was addressed by carrying out a one-way sensitivity analysis of all model inputs. The ranges of values studied were based on confidence intervals (CIs) and standard errors derived from published sources. In an alternative scenario, the sensitivity of film screening was increased and the sensitivity of digital screening was decreased. Model simulations (first-order) were also conducted to generate CIs around the total costs and QALYs.
Results
The expected QALYs in the sample of women aged ≥40 years were 13.280 with all-film screening, 13.281 with agetargeted digital screening, 13.282 with age-and density-target digital screening, and 13.281 with all-digital screening.
The expected costs per woman in the sample of women aged ≥40 years were $2,749 with all-film screening, $2,773 with age-targeted digital screening, $2,915 with age-and density-target digital screening, and $3,056 with all-digital screening.
All-film screening was the reference strategy, while the incremental cost per QALY gained was $26,500 (95% CI: 21,000 to 33,000) with age-target digital screening and $84,500 (95% CI: 75,000 to 131,000) with age-and densitytarget digital screening.
All-digital screening was dominated (less effective and more expensive than age-and density-target digital screening).
In the Medicare population (women over 65 years of age) and in the alternative scenario, the incremental cost per QALY for density-target digital screening was high (approximately or higher than $100,000 per QALY), while alldigital screening was always dominated.
The sensitivity analysis showed that the incremental cost per QALY gained was very sensitive to variations in the cost of digital screening and prevalence of dense breasts, but all-digital screening remained a not cost-effective strategy.
